Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Recognized by America's Top Doctors for 2017
Recognized by Best Doctors in America 2016
Recognized in Philadelphia magazine's annual Top Docs issues 2018 - 2020
Perelman Center for Advanced Medicine
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Cancer immunotherapyVaccinesCellular therapyPhase I trialsCAR T cells
Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren E, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie BG, Orlowski RZ: Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma Clin Cancer Res
AD Cohen, N Raje, J Fowler, K Mezzi, EC Sctoo, MV Dhodapkar: How to train your T cells: overcoming immune dysfunction in multiple myeloma Clinical Cancer Research 26 (7): 1541-1554,2020.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah A-O, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facun T, Hulin C, Kortum M, Rodriguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Pointek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD: Belantamab mafotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm randomised, open label, phase 2 study. Lancet Oncology 21 (2): 207-221,2020.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker K, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH: CRISPR-engineered T cells in patients with refractory cancer Science 367 (6481): eaba7365,2020.
Cohen AD: Myeloma: next-generation immunotherapy Hematology. American Society of Hematology Education Program. 2019 (1): 266-272,2019.
Costello CL, Gregory TK, Ali SA, Berdeja JG, Patel KK, Shah ND, Ostertag E, Martin C, Ghoddusi M, Shedlock DJ, Spear MA, Orlowski RZ, Cohen AD: Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) Blood, ASH Annual Meeting, Orlando, FL 134 (Supplement 1): 3184,2019.
Weng M, Pruteanu I, Cohen AD, Garfall AL, Tian L, Lacey SF, Fraietta J, Brogdon J, Davis M, Gonzalez VE, Levine BL, Siegel DL, Milone MC, Stadtmauer EA, June CH, Melenhorst JJ.: Response to Anti-BCMA CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma Blood, ASH Annual Meeting, Orlando, FL 134 (Supplement_1): 1909,2019.
Gertz MA, Cohen AD, Comenzo RL, Dumond C, Kastritis E, Landau HJ, Libby EN, Liedtke M, Merlini G, Sanchorawala V, Schonland SO, Wechalekar AD, Zonder JA, Kinney G: Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients Blood, ASH Annual Meeting, Orlando, FL 134 (Supplement 1): 2019.
Wang M, Pruteanu I, Cohen AD, Garfall AL, Milone MC, Tian L, Gonzalez VE, Gill S, Frey NV, Barrett DM, Ruella M, Lacey SF, Svoboda J, Chong EA, Fraietta JA, Davis M, Nasta SD, Levine BL, Siegel DL, Maude SL, Schuster SJ, Stadtmauer EA, Grupp S, Porter DL, June CH, Melenhorst JJ.: Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors Blood, ASH Annual Meeting, Orlando, FL 134 (Supplement 1): 622,2019.
Garfall AL, Cohen AD, Lacey SF, Tian L, Hwang W-T, Vogl DT, Waxman A, Lancaster E, Nelson AM, Ferthio R, Fesnak A, Lamontagne A, Brenna A, Guilliams J, Gladney WL, Melenhorst JJ, Young RM, Siegel DL, Levine BL, Brogdon J, Isaacs RE, June CH, Milone MC, Stadtmauer EA: Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma Blood, ASH Annual Meeting, Orlando, FL 134 (Supplmement 1): 1863,2019.
Perelman Center for Advanced Medicine12th Floor, South PavilionOffice #12-1753400 Civic Center Blvd
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.